Voyager Therapeutics (VYGR) Tops Q1 EPS by 287c

Voyager Therapeutics (NASDAQ: VYGR) reported Q1 EPS of $2.94, $2.87 better than the analyst estimate of $0.07. Revenue for the quarter came in at $150.48 million versus the consensus estimate of $10.04 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• SL Green Realty (SLG) PT Raised to $57 at Truist Securities
• Buffalo airport blames circuit fault, not shortage, for 3 flight delays